EVEROLIMUS
Tried EVEROLIMUS? Be part of the collective knowledge. Share your experience - your insights help others on their journey.
What Is EVEROLIMUS?
Everolimus is a semi-synthetic derivative of rapamycin that acts as a potent inhibitor of the mechanistic target of rapamycin (mTOR) complex 1. It is primarily used clinically for its immunosuppressant and anti-proliferative properties, though it is increasingly studied for its potential to modulate biological aging and enhance healthspan.
EVEROLIMUS Research & Studies
01 Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study ▸
This study demonstrated that long-term everolimus use leads to sustained reductions in tumor volume and safely manages multi-system manifestations over several years.
View Study (PubMed)EVEROLIMUS User Reviews & Experiences
*Based on large scale analysis of publicly available user experiences
Users generally view everolimus as a more bioavailable or manageable alternative to rapamycin for longevity, reporting high satisfaction with its dosing profile despite standard mTOR inhibitor side effects.
EVEROLIMUS Benefits, Dosage & Side Effects
- mTOR Inhibition: Effectively downregulates the mTORC1 pathway to promote cellular autophagy and repair.
- Tumor Reduction: Clinically proven to reduce the volume of subependymal giant cell astrocytomas and renal angiomyolipomas.
- Immunomodulation: Modulates immune response, which can be leveraged for both organ transplant safety and potential immune-aging rejuvenation.
- Skin Improvement: High percentage of users and clinical subjects report significant clearance of skin lesions and improved skin health.
- Sustained Efficacy: Long-term clinical data shows that beneficial effects on tumor reduction and lesion control are maintained over 4+ years.
- Bioavailability: Evidence suggests everolimus has better oral bioavailability and a shorter half-life than sirolimus, allowing for more precise dosing.
- Geroprotection: Research indicates it is a leading pharmacological agent for extending maximal lifespan and improving healthspan in mammalian models.
- Clinical Starting Dose: 4.5 mg/m2/day titrated to achieve a target blood trough of 5–15 ng/mL for medical conditions.
- Longevity Protocol: Users often transition to intermittent weekly dosing (e.g., 5-10mg once weekly) to minimize chronic immune suppression.
- Individualized Monitoring: Bioavailability varies significantly between individuals, making routine blood level testing essential for safety.
- Formulation Differences: Commercial tablets have significantly higher bioavailability (roughly 3x) compared to some compounded versions.
- Stomatitis: Inflammatory sores in the mouth are the most frequently reported side effect, occurring in over 40% of patients.
- Mouth Ulceration: Small, painful ulcers that typically decrease in frequency as the body adapts to the compound.
- Dyslipidemia: Potential for increased blood lipid and glucose levels, requiring periodic metabolic panels.
- Dermatological Issues: While it can clear lesions, some users experience acne-like rashes or thin skin.
- Prescription Requirement: Everolimus is an FDA-approved medication requiring a prescription, usually for TSC or oncology.
- Longevity Access: Often sourced off-label through specialized longevity clinics or via international pharmacies for anti-aging purposes.
Related Compounds
Community Reviews
Share your experience with EVEROLIMUS and help others make informed decisions.
Write a Review
Sign in to leave a review